Your browser doesn't support javascript.
loading
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim, Kunhwa; Maiti, Abhishek; Loghavi, Sanam; Pourebrahim, Rasoul; Kadia, Tapan M; Rausch, Caitlin R; Furudate, Ken; Daver, Naval G; Alvarado, Yesid; Ohanian, Maro; Sasaki, Koji; Short, Nicholas J; Takahashi, Koichi; Yilmaz, Musa; Tang, Guilin; Ravandi, Farhad; Kantarjian, Hagop M; DiNardo, Courtney D; Konopleva, Marina Y.
Afiliação
  • Kim K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pourebrahim R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rausch CR; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Furudate K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver NG; Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 127(20): 3772-3781, 2021 10 15.
Article em En | MEDLINE | ID: mdl-34255353
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos